Recently released results from two clinical trials showed that a Roche drug can dramatically reduce bleeding in hemophilia patients.
According to the company, patients who had hemophilia A but no preventative treatments experienced a 96 percent reduction in bleeding when taking Hemlibra. Patients who had taken clotting factors as a preventative measure also saw a 68 percent reduction in bleeding.
Hemlibra has already been approved for patients with inhibitors — or, antibodies that create a resistance to replacement clotting factors. The company said it hopes that the results from these new studies will help make Hemlibra the go-to for treating hemophilia A, and that the sales potential could reach $5 billion.
However, the company’s supremacy on the market could be challenged by several companies working on developing hemophilia gene therapy treatments, which, if successful, could offer a one-shot cure.
Read the full Reuters report.